The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.

Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

A drug used to treat HIV that has also shown promise in preventing infections is not a cure for those already infected, as ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.

The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir.

Gilead plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with a single shot every year ...

The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...

A new injectable drug for HIV prevention, lenacapavir, is being hailed as a potential game-changer in the fight against the ...

"Currently, there is no therapeutic cure for HIV," Sheryl Zwerski, who holds a Doctor of Nursing Practice and directs the Prevention Sciences Program at the National Institute of Allergy and ...